Pharmacology, Toxicology and Pharmaceutical Science
2 Propanol
57%
3 Hydroxyquinidine
19%
Antibiotic Agent
57%
Antibiotic Therapy
24%
Antibiotics
54%
Antiinfective Agent
24%
Azithromycin
48%
Calcium Sulfate
38%
Cefepime
19%
Ceftriaxone
48%
Cigarette Smoking
23%
Cimetidine
19%
Ciprofloxacin
19%
Creatinine
19%
Disease
29%
Elimination Rate Constant
24%
Experimental Osteomyelitis
19%
Famotidine
19%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
38%
Infection
21%
Lansoprazole
96%
Linezolid
19%
Medication Error
19%
Meropenem
19%
Normal Human
28%
Observational Study
51%
Omeprazole
70%
Pharmacodynamics
76%
Pharmacokinetics
62%
Pharmacotherapy
50%
Piperacillin Plus Tazobactam
21%
Prostacyclin
19%
Protein Binding
19%
Proton Pump Inhibitor
65%
Pulmonary Hypertension
19%
Quinidine Gluconate
38%
Ranitidine
76%
Rat Model
38%
Route of Administration
20%
Sepsis
76%
Sodium Chloride
22%
Statin (Protein)
19%
Stress Ulcer
45%
Tablet
28%
Tobramycin
38%
Toxic Injury
21%
Treprostinil
19%
Upper Gastrointestinal Bleeding
23%
Vasoactive Agent
19%
Voriconazole
19%
Keyphrases
5% Dextrose Injection
19%
Academic Conflict
19%
Adult Intensive Care Unit
21%
Adult Patients
27%
Aspiration Syndrome
19%
Calcium Sulfate
19%
Chronic Hypertension
19%
Corticosteroids
23%
Critical Care
21%
Critical Care Medicine
57%
Critical Care Research
19%
Critical Illness-related Corticosteroid Insufficiency
76%
Critically Ill Patients
81%
Epoprostenol
19%
European Society
57%
Experimental Osteomyelitis
19%
Extended-spectrum-lactamase
19%
Formulary
38%
Green Plastics
19%
Intensive Care Medicine
57%
Intensive Care Unit
22%
Intestinal Transplant
28%
Intrapulmonary Pharmacokinetics
19%
Iron Dextran
19%
Klebsiella Pneumoniae (K. pneumoniae)
19%
Lansoprazole
38%
Mobility Bundles
19%
Monitoring Management
19%
Mononuclear Cells
38%
Multispecialty
32%
Omeprazole
38%
Pediatric Patients
20%
Pharmacodynamic Response
19%
Pharmacodynamics
19%
Pharmacotherapy Trials
19%
Phenytoin
38%
Proton Pump Inhibitors
21%
Pulmonary Arterial Hypertension
19%
Ranitidine
38%
Safe Administration
19%
Septic Shock
32%
Steroid Medication
19%
Surgical Debridement
19%
Suspension Stability
19%
Sustained Low-efficiency Dialysis
19%
Tetanus
19%
Tobramycin
19%
Transplant Population
21%
Treprostinil
19%
Type 2 Diabetic Patients
19%
Medicine and Dentistry
Acute Respiratory Distress Syndrome
10%
Adult Critical Care
19%
Antiinfective Agent
17%
Antimicrobial Therapy
16%
Breathing
19%
Clavulanate Potassium
19%
Community-Acquired Pneumonia
11%
Critical Illness
96%
Decision Making
19%
Delirium
38%
Drug Therapy
49%
Endocrinology
10%
Esomeprazole
19%
Extended Spectrum Beta Lactamase
19%
Flumazenil
19%
Glucocorticoid
16%
Gram Negative Sepsis
19%
Health Care
12%
Health Care Associated Pneumonia
19%
Hospital Mortality
19%
Hydrocortisone
60%
Immunoglobulin M Antibody
19%
Injury
10%
Intensive Care
71%
Intensive Care Medicine
100%
Intensive Care Unit
64%
Iron Dextran
19%
K-Complex
19%
Klebsiella pneumoniae
19%
Lipid Pneumonia
38%
Observational Study
21%
Odds Ratio
19%
Paraprotein
19%
Pathophysiology
10%
Pediatrics Patient
14%
Penicillinase
23%
Peptic Ulcer Bleeding
19%
Predictive Factor
19%
Proton-Pump Inhibitor
38%
Pulmonary Aspiration
19%
Quinidine Gluconate
19%
Rosuvastatin
19%
Sepsis
10%
Septic Shock
10%
Shock (Circulatory)
24%
Systematic Review
10%
Tetanus
19%
Transplantation
19%
Upper Gastrointestinal Bleeding
23%
Vasoactive Agent
19%